⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Alfuzosin

آلفوزوسین

⚠ Unverified

🚻 Genito Urinary System And Sex HormonesAlpha-1 blocker

🤰 Pregnancy:Use with caution 🤱 Breastfeeding:Use with caution 👶 Children:Use with caution 👴 Older adults:Use with caution 🇮🇷 Registered in Iran ⛔ 1 contraindications 🇺🇸 FDA approved generic (ANDA) ANDA079013 ATC G04CA01

Market / country: 🇺🇸 USA

Uroxatral (US)

🧮 Dose calculator

Disease / regimen

Benign prostatic hyperplasia (BPH) · Regimen source: FDA Alfuzosin ER · 2

• Absorption is 50% lower fasting. Do not chew or crush. FDA Alfuzosin ER · 2

Formulation

Age *

Weight (kg) (optional)

Enter age (weight is optional for this regimen).

🛡️ Safety & information

Contraindications

⛔ Moderate or severe hepatic impairment; potent CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir); hypersensitivity. FDA Alfuzosin ER · 4

Warnings

• Postural hypotension and syncope; exclude prostate cancer first; intraoperative floppy iris syndrome (IFIS) in cataract surgery. FDA Alfuzosin ER · 5
• Priapism; coronary insufficiency; congenital or acquired QT prolongation; caution in severe renal impairment. FDA Alfuzosin ER · 5

Formulations

10 mg extended-release tablet (do not crush) — tablet 🇺🇸 USA FDA Alfuzosin ER · 3

👥 Special populations

🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Alfuzosin ER · 8.1
“Risk Summary Alfuzosin hydrochloride extended-release tablets are not indicated for use in women.”
🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Alfuzosin ER · 8.2
“Risk Summary Alfuzosin hydrochloride extended-release tablets is not indicated for use in women.”
👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Alfuzosin ER · 8.4
“Alfuzosin hydrochloride extended-release tablets are not indicated for use in the pediatric population.”
👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Alfuzosin ER · 8.5
“Of the total number of subjects in clinical studies of alfuzosin hydrochloride, 48% were 65 years of age and over, whereas 11% were 75 and over.”
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)ANDA079013
DailyMed (FDA label)FDA Alfuzosin ER
MedlinePlus (NIH)Alfuzosin
WHO ATC/DDDG04CA01
Darooyab (Iran)Alfuzosin

🇮🇷 Registered in Iran Darooyab · G-1515/Alfuzosin

Dosage forms with Iranian generic codes, per Darooyab.

11904 · ALFUZOSIN 10MG TAB · قرص آلفوزوسین ۱۰ میلی‌گرم

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Alfuzosin ER · 3 FDA Alfuzosin ER · 2 FDA Alfuzosin ER · 4 FDA Alfuzosin ER · 5 FDA Alfuzosin ER · SPL approval / marketing category FDA Alfuzosin ER · 8.1 FDA Alfuzosin ER · 8.2 FDA Alfuzosin ER · 8.4 FDA Alfuzosin ER · 8.5
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · G-1515/Alfuzosin
Clinical review⚠ Unverified